MX2020002560A - Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. - Google Patents
Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias.Info
- Publication number
- MX2020002560A MX2020002560A MX2020002560A MX2020002560A MX2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A
- Authority
- MX
- Mexico
- Prior art keywords
- mazindol
- substance
- treatment
- substance use
- use disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555469P | 2017-09-07 | 2017-09-07 | |
PCT/IB2018/001138 WO2019058172A1 (en) | 2017-09-07 | 2018-09-06 | MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002560A true MX2020002560A (es) | 2020-07-13 |
Family
ID=64316589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002560A MX2020002560A (es) | 2017-09-07 | 2018-09-06 | Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. |
Country Status (9)
Country | Link |
---|---|
US (1) | US11596622B2 (zh) |
EP (1) | EP3678661A1 (zh) |
JP (1) | JP2020533295A (zh) |
KR (1) | KR20200085730A (zh) |
CN (1) | CN111343979A (zh) |
BR (1) | BR112020004506A2 (zh) |
CA (1) | CA3074054A1 (zh) |
MX (1) | MX2020002560A (zh) |
WO (1) | WO2019058172A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217987A (en) * | 1989-10-30 | 1993-06-08 | Berger Stephen P | Dopamine uptake inhibitors in reducing substance abuse and/or craving |
US6323242B1 (en) * | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
FR2899476B1 (fr) | 2006-04-11 | 2008-07-04 | Assist Publ Hopitaux De Paris | Association du mazindol dans le traitement du deficit de l'attention/hyperactivite |
WO2011123496A1 (en) | 2010-03-31 | 2011-10-06 | Supernus Pharmaceuticals, Inc. | Formulations of mazindol |
US9687445B2 (en) * | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
BR112018068143A2 (pt) | 2016-03-09 | 2019-07-30 | Nls 1 Pharma Ag | forma farmacêutica unitária oral de mazindol na forma de comprimido do tipo multicamada e processo para preparar dita forma farmacêutica |
-
2018
- 2018-09-06 BR BR112020004506-3A patent/BR112020004506A2/pt unknown
- 2018-09-06 US US16/645,306 patent/US11596622B2/en active Active
- 2018-09-06 JP JP2020513594A patent/JP2020533295A/ja active Pending
- 2018-09-06 CA CA3074054A patent/CA3074054A1/en active Pending
- 2018-09-06 MX MX2020002560A patent/MX2020002560A/es unknown
- 2018-09-06 CN CN201880070488.1A patent/CN111343979A/zh active Pending
- 2018-09-06 WO PCT/IB2018/001138 patent/WO2019058172A1/en unknown
- 2018-09-06 KR KR1020207009439A patent/KR20200085730A/ko not_active Application Discontinuation
- 2018-09-06 EP EP18803756.8A patent/EP3678661A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020533295A (ja) | 2020-11-19 |
WO2019058172A1 (en) | 2019-03-28 |
KR20200085730A (ko) | 2020-07-15 |
EP3678661A1 (en) | 2020-07-15 |
US20210161865A1 (en) | 2021-06-03 |
US11596622B2 (en) | 2023-03-07 |
BR112020004506A2 (pt) | 2020-09-15 |
CA3074054A1 (en) | 2019-03-28 |
CN111343979A (zh) | 2020-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500642A1 (en) | Anti-garp antibody | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
CA3010788A1 (en) | Methods of administering vasopressors | |
MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
PH12018500814A1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
PH12018550008A1 (en) | Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2016006894A (es) | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2020002560A (es) | Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. | |
MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. |